Hims & Hers to sell Lilly's Zepbound on its telehealth platform
01/04/2025 18:28
Refiles to correct day in paragraph 1 to Tuesday from Monday April 1 (Reuters) - Telehealth firm Hims & Hers Health HIMS.N said on Tuesday it plans to sell Eli Lilly's LLY.N weight-loss drug Zepbound on its platform. Shares of the company were up 8.5% in afternoon trading. (Reporting by Sneha S K in Bengaluru; Editing by Arun Koyyur) ((Sneha.SK@thomsonreuters.com;))
Recent news on Teladoc Health
See all newsTeladoc appoints insurance executive Michael Grasher as CFO
U.S. STOCKS ON THE MOVE-Mastercard, Yum, Equinix
U.S. STOCKS ON THE MOVE-Mastercard, Starbucks, Meta
Teladoc tumbles on revenue forecast cut as BetterHelp demand shifts hurt (updated)
U.S. STOCKS ON THE MOVE-Avery Dennison, Huntington Ingalls, XPO